SABCS 2022 | Gut microbiome signatures correlate with OS in pts receiving eribulin +/- pembro for HR+ mBC

Romualdo Barroso-Sousa, MD, PhD, Dasa Oncology, Sao Paolo, Brazil, discusses an investigation into the association between fecal microbiome profiles and clinical outcomes in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC) treated with eribulin plus pembrolizumab or eribulin alone as part of a randomized Phase II study (NCT03051659). Metagenomic shotgun sequencing was performed on fecal samples collected prior to randomization from a subset of 26 participating patients. Median follow-up was 21.6 months and overall-survival (OS) was not statistically significant between two treatment arms as observed in the overall cohort. However, a metagenomic microbiome analysis suggested high diversity and composition of gut microbiome are associated with prolonged OS in HR+ MBC patients receiving eribulin with pembrolizumab. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.